KCIA
ALPN

Kingsbury Capital Investment Advisors’s Alpine Immune Sciences Inc ALPN Stock Holding History

Kingsbury Capital Investment Advisors’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-29,153
Closed -$262K – 107
2022
Q1 		$262K Buy
+29,153
New +$252K 0.29% 73

Other funds holding ALPN

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $508M AUM 163.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Kingsbury Capital Investment Advisors's ALPN Position: Q2 2022 in Review

Kingsbury Capital Investment Advisors sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2022, closing a stake of 29,153 shares — an estimated $262K sold.

Kingsbury Capital Investment Advisors first reported a position in ALPN in Q1 2022 and held it in 1 quarter. The position peaked at $262K in Q1 2022. 58 funds tracked by Wall St. Rank hold ALPN as of Q2 2022.

  • Kingsbury Capital Investment Advisors reported no remaining Alpine Immune Sciences Inc position as of Q2 2022 after selling out during the quarter.
  • Kingsbury Capital Investment Advisors sold 29,153 Alpine Immune Sciences Inc shares in Q2 2022, an estimated $262K.
  • Kingsbury Capital Investment Advisors first reported a position in Alpine Immune Sciences Inc in Q1 2022 and held it in 1 quarter.
  • Kingsbury Capital Investment Advisors's Alpine Immune Sciences Inc position peaked at $262K in Q1 2022.
  • 58 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2022.

Based on Kingsbury Capital Investment Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.